ZHANG Bi-xiang, ZOU Wei. Adjuvant Lenvatinib in Combination With TACE for HCC Patients With High Risk of Postoperative Relapse: Updated of LANCE Study[J]. Journal of Evidence-Based Medicine, 2021, 21(6): 329-331. DOI: 10.12019/j.issn.1671-5144.2021.06.003
|
Citation:
|
ZHANG Bi-xiang, ZOU Wei. Adjuvant Lenvatinib in Combination With TACE for HCC Patients With High Risk of Postoperative Relapse: Updated of LANCE Study[J]. Journal of Evidence-Based Medicine, 2021, 21(6): 329-331. DOI: 10.12019/j.issn.1671-5144.2021.06.003
|
ZHANG Bi-xiang, ZOU Wei. Adjuvant Lenvatinib in Combination With TACE for HCC Patients With High Risk of Postoperative Relapse: Updated of LANCE Study[J]. Journal of Evidence-Based Medicine, 2021, 21(6): 329-331. DOI: 10.12019/j.issn.1671-5144.2021.06.003
|
Citation:
|
ZHANG Bi-xiang, ZOU Wei. Adjuvant Lenvatinib in Combination With TACE for HCC Patients With High Risk of Postoperative Relapse: Updated of LANCE Study[J]. Journal of Evidence-Based Medicine, 2021, 21(6): 329-331. DOI: 10.12019/j.issn.1671-5144.2021.06.003
|
DownLoad: